SciBase Strengthens Partnership with Castle Biosciences Through New Order and Clinical Studies

SciBase and Castle Biosciences: Pioneering Dermatological Innovations

SciBase Holding AB, a frontrunner in the field of AI-driven dermatological devices, has made significant strides in its partnership with Castle Biosciences, a prominent entity in molecular diagnostics. On September 8, 2026, SciBase announced that it secured an additional order as part of its ongoing collaboration with Castle Biosciences. This new order aims to accelerate the ongoing clinical study while also laying the groundwork for a subsequent clinical venture.

The value of this order amounts to approximately $0.6 million (about MSEK 5) and includes the provision of the portable Nevisense Go pen device and electrodes. This collaboration initially began in 2025, and the first study focuses on predicting relapses in atopic dermatitis (AD), a chronic condition that significantly affects the skin's health and resilience. As disease prevalence increases, so does the demand for advanced diagnostic solutions which can provide timely interventions and better outcomes for patients.

Pia Renaudin, CEO of SciBase, expressed enthusiasm about the progression of this collaboration. "We're thrilled with the rapid patient recruitment in our first joint study, and this additional order reflects our expanding partnership," she commented. The effort not only emphasizes SciBase's commitment to integrating cutting-edge technology in dermatology but also showcases the dedicated collaborative approach with Castle Biosciences, which specializes in developing molecular diagnostics for various skin conditions.

This additional order signifies a positive trajectory for both companies as they strive to enhance treatment standards for patients grappling with skin barrier dysfunctions. As patient needs evolve, their focus on combined expert knowledge will pave the way for more effective therapies that promise an improvement in the quality of life for those affected by skin ailments.

The deliveries associated with the new order are expected to commence in the fourth quarter of 2026, positioning both SciBase and Castle Biosciences at the forefront of dermatological innovation. With a foundation built on over two decades of research undertaken at the Karolinska Institute in Stockholm, SciBase is committed to advancing the diagnostic capabilities of dermatology.

The Significance of the Nevisense Technology

Nevisense, SciBase's flagship product, is a groundbreaking point-of-care system that utilizes a combination of artificial intelligence and advanced electrical impedance spectroscopy (EIS) technology. This platform is designed to facilitate the early detection and prevention of skin-related issues, ensuring comprehensive management of skin health.

The collaboration with Castle Biosciences represents a vital step toward extending the horizons of both organizations' capabilities in providing early intervention for atopic dermatitis and perhaps other skin conditions in the future. The urgency for such advancements cannot be overstated, given the rising incidence and recognition of skin diseases in today's healthcare landscape.

Organizations like SciBase, committed to minimizing patient suffering and enhancing clinicians' abilities to make accurate diagnoses, are pivotal in promoting better health outcomes. By investing in innovative technology and strategic partnerships, they aim to reduce healthcare costs and ensure accessibility to vital treatments for all patients.

In summary, the additional order from Castle Biosciences is not only a testament to the ongoing success of the partnership but also reiterates the critical need for continual evolution within dermatology to meet patient demands. This collaboration sets a new benchmark for what can be achieved when advanced technology meets thorough clinical research, ultimately working to transform the lives of those managing skin health challenges.

For further information on this partnership, visit SciBase's official website.